Of these, 5,967 were treated with semaglutide while the remaining participants were on other anti-diabetic therapies, such as metformin, insulin, SGLT2 inhibitors and other GLP-1 analogs
GLP-1 Agonists Market size was valued at US$ 37,113.2 billion in 2025 and is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026-2032
Genes encoding WRKY transcription factors, PR-proteins, a phenylalanine ammonia-lyase (PAL) and a GST were up-regulated in infected berries (Agudelo-Romero et al., 2015)
If you know you want to try a weight loss medication, but cant get behind the idea of sticking yourself with a needle, it makes sense to narrow the field to these two options
The absolute increase was therefore small, although the condition can cause sudden, painless and potentially permanent vision loss
This can delay or prevent treatment for individuals who could benefit significantly from these medications